1
Yoshikawa Seiji, Emori Eita, Matsuura Fumiyoshi, Clark Richard, Ikuta Hironori, Yasuda Nobuyuki, Nagakura Tadashi, Yamazaki Kazuto, Aoki Mika: Xanthine derivatives as dpp-iv inhibitors. Eisai, August 27, 2003: EP1338595-A2 (67 worldwide citation)

The present invention provides novel compounds exhibiting an excellent DPPIV inhibition effect. The compounds are represented by the formula: wherein, m is 0 or 1; n is 0; R, R, R, R, R, R, R, R, R, R, R, and R each represent a hydrogen atom; X represents an alkynyl group, an aryl group, and such, w ...


2
Asano Osamu, Harada Hitoshi, Hoshino Yorihisa, Yoshikawa Seiji, Inoue Takashi, Horizoe Tatsuo, Yasuda Nobuyuki, Nagata Kaya, Nagaoka Junsaku, Murakami Manabu, Kobayashi Seiichi: Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes. Eisai, November 22, 2000: EP1054012-A1 (62 worldwide citation)

The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonistic action. A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof ha ...


3
Yoshikawa Seiji, Emori Eita, Matsuura Fumiyoshi, Richard Clark, Ikuta Hironori, Kira Kazunobu, Yasuda Nobuyuki, Nagakura Tadashi, Yamazaki Kazuto: Novel fused imidazole derivative. Eisai, March 16, 2005: EP1514552-A1 (56 worldwide citation)

The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substi ...


4
Yasuda Nobuyuki, Yamazaki Kazuto: (Ja) 併用医薬, (En) Combination drug. Eisai, Yasuda Nobuyuki, Yamazaki Kazuto, SHIMIZU Hatsushi, April 8, 2004: WO/2004/028524 (56 worldwide citation)

(EN) It is intended to provide a drug comprising a combination of a dipeptidyl peptidase IV (DPPIV) inhibitor with biguanide characterized by potentiating the effect of activated glucagon-like peptide-1 (GLP-1) in blood and/or activated glucagon-like peptide-2 (GLP-2) in blood.(JA) 本発明は、血中活性型グルカゴン様ペ ...


5
Yasuda Nobuyuki, Yamazaki Kazuto: Combination drug. Eisai, July 27, 2005: EP1557165-A1 (36 worldwide citation)

The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2).


6
Asano Osamu, Harada Hitoshi, Yoshikawa Seiji, Watanabe Nobuhisa, Inoue Takashi, Horizoe Tatsuo, Yasuda Nobuyuki, Ohashi Kaya, Minami Hiroe, Nagaoka Junsaku, Murakami Manabu, Kobayashi Seiichi, Tanaka Isao, Kawata Tsutomu, Shimomura Naoyuki, Akamatsu Hiroshi, Ozeki Naoki, Shimizu Toshikazu, Hayashi Kenji, Haga Toyokazu: Fused imidazole compounds and remedies for diabetes mellitus. Eisai, July 10, 2002: EP1221444-A1 (32 worldwide citation)

The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action. That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, ...


7
Tsuchiya Susumu, Yasuda Nobuyuki, Matsumoto Toshifumi, Hiratsuka Kozo, Iizuka Hiroyuki, Hukuzaki Atsusi, Matsunaga Kouichi: Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same. Tokyo Tanabe Co, September 8, 1999: EP0940387-A1 (14 worldwide citation)

The present invention relates to phenylethanolamine compounds represented by general formula ÄIÜ: (where R1 represents hydrogen or halogen; R2 represents hydrogen, hydroxy, lower alkoxy, lower alkoxy substituted with one or two lower alkoxycarbonyl or carboxy groups, lower alkoxy substituted with lo ...


8
Asano Osamu, Harada Hitoshi, Hoshino Yorihisa, Yoshikawa Seiji, Inoue Takashi, Horizoe Tatsuo, Yasuda Nobuyuki, Nagata Kaya, Nagaoka Junsaku, Murakami Manabu, Kobayashi Seiichi, Ohashi Kaya: Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus. Eisai, April 9, 2003: EP1300147-A1 (12 worldwide citation)

The present invention relates to the use of A2 receptor antagonists and their pharmacologically acceptable salts or hydrates for preparing medicaments for preventing or treating diabetes mellitus or diabetic complications, and for preparing improving agents for impaired glucose tolerance, potentiati ...


9
Harada Hitoshi, Asano Osamu, Ueda Masato, Miyazawa Shuhei, Kotake Yoshihiko, Kabasawa Yasuhiro, Yasuda Masahiro, Yasuda Nobuyuki, Iida Daisuke, Nagakawa Junichi, Hirota Kazuo, Nakagawa Makoto: Pyrimidine compound and medicinal composition thereof. Eisai, July 21, 2004: EP1439175-A1 (11 worldwide citation)

The present invention provides a novel pyrimidine compound having an excellent adenosine receptor (A1, A2A, A2B receptor) antagonistic action. More specifically, it provides a compound represented by the following formula, a salt thereof or a solvate of them. In the formula, R and R are the same as ...


10
Yasuda Nobuyuki C O Sony Corpo: Sampling frequency converting device and memory address control device.. Sony, August 2, 1995: EP0665546-A2 (10 worldwide citation)

A sampling frequency converting device is disclosed. A memory unit stores an input signal Dsi having an input sampling frequency Fsi. An interpolation unit interpolates the readout signal from the storage unit. A sampling frequency ratio detection unit detects the current sampling frequency ratio Rn ...